Lymphoma Clinical Trials in Texas

Showing 381-399 of 399 trials

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

NCT00634452

To establish the safety and tolerability profile of MDX-1401 in patients with relapsed or refractory Hodgkin's Lymphoma (HL).

Hodgkin's Lymphomas

Bristol-Myers Squibb22 participantsStarted Feb 2008

Atlanta, Georgia, United States • Chicago, Illinois, United States • New York, New York, United States +3 more locations

TERMINATEDPhase 299 miles

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

NCT00843050

The purpose of this study is to determine whether P276-00 is safe and effective in treatment of Mantle Cell Lymphoma that is recurred after or not responding to at least one previous line of treatment.

Mantle Cell Lymphoma

Piramal Enterprises Limited13 participantsStarted Nov 2009

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Rochester, Minnesota, United States +17 more locations

PreviousPage 20 of 20

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Lymphoma Trials in Other Cities

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Other Conditions in Texas